|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date25 Dec 2020 |
A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and multiple escalating dose administration.
100 Clinical Results associated with Innocare Pharma Australia Pty Ltd
0 Patents (Medical) associated with Innocare Pharma Australia Pty Ltd
100 Deals associated with Innocare Pharma Australia Pty Ltd
100 Translational Medicine associated with Innocare Pharma Australia Pty Ltd